title: Confirmation on the immunogenicity assay used in the SB4 phase III study: response to the comments by Meacci et al.
authors.affiliation: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
authors.forename: Paul
authors.initials: P
authors.lastname: Emery
authors.affiliation: Institute of Rheumatology, Prague, Czech Republic.
authors.forename: Jiří
authors.initials: J
authors.lastname: Vencovský
authors.affiliation: Samsung Bioepis Co., Ltd. Incheon, Republic of Korea.
authors.forename: Jung Won
authors.initials: JW
authors.lastname: Kang
authors.affiliation: Samsung Bioepis Co., Ltd. Incheon, Republic of Korea.
authors.forename: Jeehoon
authors.initials: J
authors.lastname: Ghil
mesh_terms: D000906:Antibodies / Q000032:analysis; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001681:Biological Assay; D000068800:Etanercept / Q000627:therapeutic use*; D007118:Immunoassay; D007166:Immunosuppressive Agents / Q000627:therapeutic use*
chemical_list: D000906:Antibodies; D007166:Immunosuppressive Agents; D000068800:Etanercept
keywords: Disease Activity; Inflammation; Treatment